The relationship between natural killer cells (NK) and cells of the T lineage has been obscured by the existence of poorly characterized clones of presumed NK origin. We have analyzed nine of these cloned cell lines displaying varying levels of cytotoxic activity against NKS YAC-1 target cells for rearrangement and expression of the genes encoding the alpha, beta, and gamma chains of the T cell receptor for antigen. Rearrangements at both the TcR beta and gamma loci were detected in all clones often at both alleles. Rearrangement patterns at the TcR beta locus were identical in several clones, despite different degrees of cytotoxicity. T cell receptor alpha, beta, and gamma genes were expressed as full length transcripts in all clones regardless of their levels of cytotoxic activity. To explore the involvement of cell surface molecules in the cytolytic events, studies were undertaken to determine whether cytotoxic activity could be inhibited by antibodies against CD3, LFA-I, and H-2KdDd. In two selected clones, both alpha and beta chains of the LFA-I molecule were expressed but only monoclonal antibodies against the alpha chain significantly blocked cytotoxicity. Cytotoxicity was also inhibited by monoclonal antibodies against epitopes of H-2KdDd and CD3, the extent of inhibition correlating with the level of surface expression on both clones. These data suggest that conventional alpha/beta heterodimers may be necessary but not sufficient for target cell recognition by these clones. Since T cell receptor rearrangement and expression occur normally in the T cell lineage but not the NK lineage, these results also indicate that a subpopulation of cells with non-MHC-restricted killer activity lies on the T cell differentiation pathway and is selected by in vitro growth with IL-2. The limited rearrangement pattern observed can be explained if only a small subpopulation of T cells is capable of non-MHC-restricted killing, and if certain rearrangements favor self-MHC recognition which is known to block cytolysis in the NK system.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0008-8749(89)90377-8 | DOI Listing |
BMC Complement Med Ther
January 2025
Division of Pharmacology and Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand.
Background: Plant flavonoids such as quercetin are useful for both the therapeutic and preventive care of a variety of illnesses. Nevertheless, their antitumor efficacy against KON oral cancer is still unknown. Therefore, the aim of this investigation was to examine quercetin's anti-growth, anti-migrative, and anti-invasive characteristics.
View Article and Find Full Text PDFBMC Complement Med Ther
January 2025
Department of Biotechnology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, India.
The spreading of COVID-19 has posed a risk to global health, especially for lung cancer patients. An investigation is needed to overcome the challenges of COVID-19 pathophysiology and lung cancer disease. This study was designed to evaluate the phytoconstituents in Punica granatum peel (PGP), its anti-lung cancer activity, and in silico evaluation for antiviral potential.
View Article and Find Full Text PDFCell Mol Biol Lett
January 2025
Clinical Research Center, Jiading District Central Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, 201800, China.
Background: Circular (circ)RNAs have emerged as crucial contributors to cancer progression. Nonetheless, the expression regulation, biological functions, and underlying mechanisms of circRNAs in mediating hepatocellular carcinoma (HCC) progression remain insufficiently elucidated.
Methods: We identified circUCK2(2,3) through circRNA sequencing, RT-PCR, and Sanger sequencing.
Acta Pharmacol Sin
January 2025
School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
FMS-like tyrosine kinase-3 (FLT3), a class 3 receptor tyrosine kinase, can be activated by mutations of internal tandem duplication (FLT3-ITD) or point mutations in the tyrosine kinase domain (FLT3-TKD), leading to constitutive activation of downstream signaling cascades, including the JAK/STAT5, PI3K/AKT/mTOR and RAS/MAPK pathways, which promote the progression of leukemic cells. Despite the initial promise of FLT3 inhibitors, the discouraging outcomes in the treatment of FLT3-ITD-positive acute myeloid leukemia (AML) promote the pursuit of more potent and enduring therapeutic approaches. The histone acetyltransferase complex comprising the E1A binding protein P300 and its paralog CREB-binding protein (p300/CBP) is a promising therapeutic target, but the development of effective p300/CBP inhibitors faces challenges due to inherent resistance and low efficacy, often exacerbated by the absence of reliable clinical biomarkers for patient stratification.
View Article and Find Full Text PDFLeukemia
January 2025
Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!